Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1161-1170 of 2916 for cancer

Edit search filters
  1. A Study Of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab In Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

    Rochester, MN

  2. A Study To Compare Three Chemotherapy Regimens For The Treatment Of Patients With Newly- Diagnosed Mantle Cell Lymphoma

    Jacksonville, FL, Rochester, MN

  3. A Study of Everolimus with or without Bevacizumab for Treating Patients with Advanced Kidney Cancer that Progressed after First-Line Therapy

  4. AZD0120 In Relapsed/Refractory Multiple Myeloma (DURGA-1)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study in Second Line Metastatic Colorectal Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. A Study Of Lower Radiotherapy Dose To Treat Children With CNS Germinoma

    Rochester, MN

  7. Testing The Addition Of Ixazomib To Lenalidomide In Patients With Evidence Of Residual Multiple Myeloma, OPTIMUM Trial

    La Crosse, WI, Rochester, MN

  8. A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  9. XmAb18968 (CD3-CD38) In Relapsed Or Refractory Acute Leukemia And T Cell Lymphoblastic Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. A Study of Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia, or Refractory or Relapsed Acute Myelogenous Leukemia

    Rochester, MN

.

Mayo Clinic Footer